Navigation Links
XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
Date:10/25/2007

NEW YORK, October 25 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB)(LSE: XTL)(TASE: XTL) today announced that it has entered into definitive agreements with institutional investors relating to a private placement of an aggregate of $9.6 million in gross proceeds of ordinary shares, represented by American Depositary Receipts (ADRs). The lead investors in the transaction are Perceptive Life Sciences Fund, Quogue Capital LLC, SCO Capital Partners and Versant Capital.

Ron Bentsur, Chief Executive Officer of XTL, commented, "We are very pleased to have consummated this financing with high-quality investors in the biotechnology sector in the U.S. Following this offering, we believe that we will have sufficient capital to execute our business plan and, more importantly, to reach what we believe could be a major value-enhancing milestone - the completion of our on-going randomized, placebo-controlled Phase IIb trial of Bicifadine in diabetic neuropathic pain."

Pursuant to the securities purchase agreements, the Company will, following the closing, issue approximately 7.1 million ADRs, representing approximately 71 million ordinary shares. No warrants were issued in the transaction. XTL has agreed to register the ordinary shares and list the ADRs for trading on the Nasdaq Stock Market.

Closing of the transaction is conditional upon, among other things, the delisting of the Company's ordinary shares from the Official List of the United Kingdom Listing Authority, scheduled to take place at 8:00 am (London Time) on October 31, 2007.

Punk, Ziegel & Company, L.P. and Brean Murray, Carret & Co., LLC acted as placement agents in the transaction.

ABOUT XTL BIOPHARMACEUTICALS LTD.'/>"/>

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... -   JOLT , a leading technology accelerator, announced ... growing portfolio of startups. Next-level tech and boundary-pushing innovation ... JOLT accelerator, and Cohort four is no exception, with ... Since its launch in July 2012, JOLT has produced ... Now at 23 investments, JOLT,s portfolio has an overall ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health ... disease, announced the hire of Brad Towle ... will be responsible for driving the company,s sales growth, ... experience in healthcare, and specifically his past role in ... to the company at this pivotal time in the ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... , , ... 8 /PRNewswire-Asia/ -- The Jiangsu Government,s,Science and Technology Department ... Achievements Transformational Grant - to support the,research and development ... grant recipient and administrator, Shenzhen Beike,Biotechnology Co., Ltd. ( ...
... , NORTH BILLERICA, Mass., Dec. 29 ... of instruments for measuring cellular bioenergetics, announced that TheScientist ... 2009 Top Ten Innovation. , A panel of scientific experts ... the first instrument to measure the two energy pathways of ...
... , ORLANDO, Fla., Dec. 28 ... a leading consumer genomics and biotechnology company ( www.genelinkbio.com ), ... as its interim Chief Executive Officer, effective December 28, 2009. ... with more than 25 years of experience building high performance ...
Cached Biology Technology:Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 2Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 3Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 4TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009 2David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 2David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 3David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 4
(Date:7/28/2014)... Wyss Institute for Biologically Inspired Engineering at Harvard ... will be commercialized by a newly formed private ... and personalized medicine products. The announcement ... of Technology Development (OTD) and the start-up Emulate ... automated human Organs-on-Chips platform. , "This is ...
(Date:7/27/2014)... wiped them out if it had taken place slightly ... fresh study using up-to-date fossil records and improved analytical ... of the prehistoric creatures, demise, some 66 million years ... years before a 10km-wide asteroid struck what is now ... volcanic activity, changing sea levels and varying temperatures. ...
(Date:7/27/2014)... studies have shown the potential for global climate change ... the most part, ignored the interactions between increasing temperature ... known to damage crops. , A new study involving ... quite significant, suggesting that policymakers need to take both ... security. , The study looked in detail at global ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Dinosaurs fell victim to perfect storm of events, study shows 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... the most rapidly increasing food production system worldwide through ... 2009 issue of BioScience . The assessment, by ... Ann Arbor, notes that despite well-publicized concerns about ... practiced well, be no more damaging to biodiversity than ...
... has worked out how some newly discovered light sensors ... brain. The report appears online this week in ... small number of nerve cells in the retina that ... retinarods and conesmelanopsin-containing cells are not used for seeing ...
... DNA modification in lung cancer, a team of international researchers ... They say that "silencing" of a single gene in lung ... cells, contributing to cancer development and progression. In the ... journal of the American Association for Cancer Research, they also ...
Cached Biology News:Aquaculture's growth seen as continuing 2Bright lights, not-so-big pupils 2Bright lights, not-so-big pupils 3In lung cancer, silencing one crucial gene disrupts normal functioning of genome 2In lung cancer, silencing one crucial gene disrupts normal functioning of genome 3
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Request Info...
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
Biology Products: